New developments in the role of cytokines and chemokines in inflammatory myopathies

Current Opinion in Rheumatology

Volumn 10, Issue 6, 1998, Pages 521-529

  Lundberg, Ingrid E ^a   Nyberg, Pernilla ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CYTOKINE; INTERLEUKIN 1; MACROPHAGE INFLAMMATORY PROTEIN 1; MONOKINE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

CAPILLARY; CHRONIC INFLAMMATION; DERMATOMYOSITIS; ENDOTHELIUM CELL; HUMAN; IMMUNOREGULATION; INCLUSION BODY MYOSITIS; MYOPATHY; PATHOGENESIS; POLYMYOSITIS; PRIORITY JOURNAL; REVIEW; TISSUE DISTRIBUTION; VENULE;

CHEMOKINES; CYTOKINES; DERMATOMYOSITIS; HUMANS; INFLAMMATION MEDIATORS; MONOKINES; MYOSITIS; MYOSITIS, INCLUSION BODY; POLYMYOSITIS;

EID: 0031767533     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-199811000-00004     Document Type: Review

References (53)

1. Arahata K, Engel AG: Monoclonal antibody analysis of mononuclear cells in myopathies: I: Quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells. Ann Neurol 1984, 16:193-208.
2. Sivakumar K, Dalakas MC: Inclusion body myositis and myopathies. Curr Opin Neurol 1997, 10:413-420.
3. Engel AG, Arahata K: Monoclonal antibody analysis of mononuclear cells in myopathies: II: Phenotypes of autoinvasive cells in polymyositis and inclusion body myositis. Ann Neurol 1984, 16:209-215.
4. Arahata K, Engel AG: Monoclonal antibody analysis of mononuclear cells in myopathies: V: Identification and quantitation of 18+ cytotoxic and T8+ suppressor cells. Ann Neurol 1988, 23:493-499.
5. Cherin P. Recognition and management of myositis. Drugs 1997, 54:39-49.
6. Engel AG, Arahata K: Mononuclear cells in myopathies: quantitation of functionally distinct subsets, recognition of antigen-specific cell-mediated cytotoxicity in some diseases, and implications for the pathogenesis of the different inflammatory myopathies. Hum Pathol 1986, 17:704-721.
7. Emslie-Smith AM, Engel AG: Microvascular changes in early and advanced dermatomyositis: a quantitative study. Ann Neurol 1990, 27:343-356.
8. Hohlfeld R, Engel AG: The immunobiology of muscle. Immunol Today 1994, 15:269-274.
9. Holmdahl R, Malmstrom V, Vuorio E: Autoimmune recognition of cartilage collagens. Ann Med 1993, 25:251-264.
10. Constantinescu CS, Hilliard B, Fujioka T, Bhopale MK, Calida D, Rostami AM: Pathogenesis of neuroimmunologic diseases: Experimental models. Immunol Res 1998, 17:217-227.
11. Engel AG, Hohlfeld R, Banker BQ: The polymyositis and dermatomyositis Syndromes. In Myology, edr 2. Edited by Engel AG, Franzini-Armstrong C. New York: McGraw Hill; 1994:1335-1383.
12. Janeway C, Travers P: T-cell mediated immunity. In Immunobiology - The Immune System in Health and Disease, edr 2. Edited by Janeway C, Travers P. New York: Churchill Livingstone; 1996:7:1-7:41.
13. Mantovani A: The interplay between primary and secondary cytokines: cytokines involved in the regulation of monocyte recruitment. Drugs 1997, 1:15-23. Discusses how regulation of the chemokine and cytokine systems can be achieved by regulating agonist production or altering the expression of receptors for these molecules.
14. Romagnani S, Parronchi P, D'Elios MM, Romagnani P, Annunziato F, Piccinni MP, et al.: An update on human Th1 and Th2 cells. Int Arch Allergy Immunol 1997, 113:153-156.
15. Romagnani S: Lymphokine production by human T cells in disease states. Ann Rev Immunol 1994, 12:227-257.
16. Wahl SM: Transforming growth factor beta: the good, the bad, and the ugly. J Exp Med 1994, 180:1587-1590.
17. Kehrl JH: Transforming growth factor-beta: an important mediator of immunoregulation. Int J Cell Cloning 1991, 9:438-450.
18. Feldmann M, Brennan F, Paleolog E, Taylor P, Maini RN. Anti-tumor necrosis factor alpha therapy of rheumatoid arthritis: mechanism of action. Eur Cytokine Network 1997, 8:297-300. This paper presents a very promising anticytokine therapy and discusses the mechanims of monoclonal antibodies against cytokines in the treatment of rheumatoid arthritis.
19. Luster AD: Chemokines: chemotactic cytokines that mediate inflammation. N Engl J Med 1998, 338:436-445.
20. Schluger NW, Rom WN: Early responses to infection: chemokines as mediators of inflammation. Curr Opin Immunol 1997, 9:504-508.
21. Adams EM, Kirkley J, Eidelman G, Dohlman J, Plotz PH: The predominance of beta (CC) chemokine transcripts in idiopathic inflammatory muscle diseases. Proc Assoc Am Physicians 1997, 109:275-285. The presence of cytokine and chemokine transcripts in polymyositis and dermatomyositis is reported. MIP-1α was the chemokine most commonly expressed in 13 of 14 cases of polymyositis and dermatomyositis. There was no difference in cytokine or chemokine pattern between polymyositis and dermatomyositis.
22. Lundberg I, Brengman JM, Engel AG: Analysis of cytokine expression in muscle in inflammatory myopathies, Duchenne dystrophy, and non-weak controls. J Neuroimmunol 1995, 63:9-16.
23. Lundberg I, Ulfgren AK, Nyberg P, Andersson U, Klareskog L: Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathies. Arthritis Rheum 1997, 40:865-874. No difference in cytokine expression pattern between polymyositis, IBM, and dermatomyositis was detected. Predominant interleukin-1α and TGF-β expression in the blood vessels was seen. Authors concluded that there might be an importance for the endothelial cells in the inflammatory process.
24. Tews DS, Goebel HH: Cytokine expression profile in idiopathic inflammatory myopathies. J Neuropathol Exp Neurol 1996, 55:342-347.
25. Lindberg C, Oldfors A, Tarkowski A: Local T-cell proliferation and differentiation in inflammatory myopathies. Scand J Immunol 1995, 41:421-426.
26. Schubert W, Kontozis L, Sticker G, Schwan H, Haraldsen G, Jerusalem F: Immunofluorescent evidence for presence of interleukin-1 in normal and diseased human skeletal muscle. Muscle Nerve 1988, 11:890-892.
27. Belec L, Authier FJ, Chazaud B, Piedouillet C, Barlovatz-Meimon G, Gherardi RK: Interleukin (IL)-1 beta and IL-1 beta mRNA expression in normal and diseased skeletal muscle assessed by immunocytochemistry, immunoblotting and reverse transcriptase-nested polymerase chain reaction. J Neuropathol Exp Neurol 1997, 56:651-663. This report highlights the importance of using optimized methods in order to get reliable results to detect interleukin-1 transcripts.
28. Authier FJ, Mhiri C, Chazaud B, Christov C, Cherin P, Barlovatz-Meimon G, Gherardi RK: Interleukin-1 expression in inflammatory myopathies: evidence of marked immunoreactivity in sarcoid granulomas and muscle fibres showing ischaemic and regenerative changes. Neuropathol Appl Neurobiol 1997, 23:132-140. Interleukin-1α expression in inflammatory cells, muscle fibers, and vessels is reported.
29. Girard JP, Springer TA: High endothelial venules (HEVs): specialized endothelium for lymphocyte migration. Immunol Today 1995, 16:449-457.
30. Mantovani A, Bussolino F, Dejana E: Cytokine regulation of endothelial cell function. FASAB J 1992, 6:2591-2599.
31. Confalonieri P, Bernasconi P, Cornelio F, Mantegazza R: Transforming growth factor-beta 1 in polymyositis and dermatomyositis correlates with fibrosis but not with mononuclear cell infiltrate. J Neuropathol Exp Neur 1997, 56:479-484. This report suggests a correlation between TGF-β1 and connective tissue proliferation in inflammatory myopathy; the authors speculate that the increase of TGF-β1 may be linked to the ischemic muscle damage.
32. Husmann I, Soulet L, Gautron J, Martelly I, Barritault D: Growth factors in skeletal muscle regeneration. Cytokine Growth Factor Rev 1996, 7:249-258.
33. Lefaucheur JP, Gjata B, Lafont H, Sebille A: Angiogenic and inflammatory responses following skeletal muscle injury are altered by immune neutralization of endogenous basic fibroblast growth factor, insulin-like growth factor-1 and transforming growth factor-beta 1. J Neuroimmunol 1996, 70:37-44.
34. Gamble JR, Khew-Goodall Y, Vadas MA: Transforming growth factor-beta inhibits E-selectin expression on human endothelial cells. J Immunol 1993, 150:4494-4503.
35. De Bleecker JL, Engel AG: Expression of cell adhesion molecules in inflammatory myopathies and Duchenne dystrophy. J Neuropathol Exp Neurol 1994, 53:369-376.
36. Kalovidouris AE: The role of cytokines in polymyositis: interferon-gamma induces class II and enhances class I major histocompatibility complex antigen expression on cultured human muscle cells. J Lab Clin Med 1992, 120:244-251.
37. Ulfgren AK, Lindblad S, Klareskog L, Andersson J, Andersson U: Detection of cytokine producing cells in the synovial membrane from patients with rheumatoid arthritis. Ann Rheum Dis 1995, 54:654-661.
38. Mussener A, Litton MJ, Lindroos E, Klareskog L: Cytokine production in synovial tissue of mice with collagen-induced arthritis (CIA). Clin Exp Immunol 1997, 107:485-493.
39. Mojcik CF, Shevach EM: Adhesion molecules: a rheumatologic perspective. Arthritis Rheum 1997, 40:1-2. A comprehensive overview of selectins, integrins, and immunoglobulin superfamily molecules.
40. Cid MC, Grau JM, Casademont J, Tobias E, Picazo A, Coll-Vinent B, et al.: Leucocyte/endothelial cell adhesion receptors in muscle biopsies from patients with idiopathic inflammatory myopathies (IIM). Clin Exp Immunol 1996, 104:467-473.
41. Tews DS, Goebel HH: Expression of cell adhesion molecules in inflammatory myopathies. J Neuroimmunol 1995, 59:185-194.
42. Bazan JF, Bacon KB, Hardiman G, Wang W, Soo K, Rossi D, et al.: A new class of membrane-bound chemokine with a CX3C motif. Nature 1997, 385:640-644. The authors describe a new chemokine, noteworthy as it is detected in skeletal muscle.
43. Sikorski EE, Hallmann R, Berg EL, Butcher EC: The Peyer's patch high endothelial receptor for lymphocytes, the mucosal vascular addressin, is induced on a murine endothelial cell line by tumor necrosis factor-alpha and IL-1. J Immunol 1993, 151:5239-5250.
44. Park JH, Olsen NJ, King L, Vital T, Buse R, Kari S, et al.: Use of magnetic resonance imaging and P-31 magnetic resonance spectroscopy to detect and quantify muscle dysfunction in the amyopathic and myopathic variants of dermatomyositis. Arthritis Rheum 1995, 38:68-77.
45. Fang CH, Li BG, James JH, Fischer JE, Hasselgren PO: Cytokines block the effects of insulin-like growth factor-I (IGF-I) on glucose uptake and lactate production in skeletal muscle but do not influence IGF-I-induced changes in protein turnover. Shock 1997, 8:362-367. The present paper tests the hypothesis that proinflammatory cytokines counteract the anabolic effects of insulin-like growth factor I (IGF-I) in muscle tissue.
46. Leon-Monzon M: Interleukin-1 is toxic to human muscle. Neurology 1994, 44(suppl 2):A132.
47. Baracos V, Rodemann HP, Dinarello CA, Goldberg AL: Stimulation of muscle protein degradation and prostaglandin E2 release by leukocytic pyrogen (interleukin-1): a mechanism for the increased degradation of muscle proteins during fever. N Engl J Med 1983, 308:553-558.
48. Clowes G Jr, George BC, Villee C Jr, Saravis CA: Muscle proteolysis induced by a circulating peptide in patients with sepsis or trauma. N Engl J Med 1983, 308:545-552.
49. Shreeniwas R, Koga S, Karakurum M, Pinsky D, Kaiser E, Brett J, et al.: Hypoxia-mediated induction of endothelial cell interleukin-1 alpha: an autocrine mechanism promoting expression of leukocyte adhesion molecules on the vessel surface. J Clin Invest 1992, 90:2333-2339.
50. Falanga V, Qian SW, Danielpour D, Katz MH, Roberts AB, Sporn MB: Hypoxia upregulates the synthesis of TGF-beta 1 by human dermal fibroblasts. J Invest Dermatol 1991, 97:634-637.
51. Niinikoski J, Paljarvi L, Laato M, Lang H, Panelius M: Muscle hypoxia in myositis. J Neurol Neurosurg Psychiat 1986, 49:1455.
52. Authier FJ, Chazaud B, Mhiri C, Eliezer-Vanerot MC, Poron F, Barlovatz-Meimon G, Gherardi RK: Interleukin-1 expression in normal motor endplates and muscle fibers showing neurogenic changes. Acta Neuropathol 1997, 94:272-279. The authors conclude that interleukin-1 expressed by muscle fibers in pathological conditions seems to be associated with myofibrillar protein breakdown and regeneration.
53. Lundberg I: Effects of corticosteroid treatment on IL-1 alpha and IL-1 beta expression in muscle tissue in patients with inflammatory myopathies [abstract]. Arthritis Rheum 1997, 40:180. Interleukin-1α was found in the endothelial cells during corticosteroid treatment, although the inflammatory infiltrates were abolished.